Im Jong-hoon Appointed President of Hanmi Science
Post-Merger Goal of Hanmi Healthcare: "Annual Sales of 50 Billion KRW"
Key products secured by Hanmi Science through the merger with Hanmi Healthcare include the adhesion prevention agent 'Gadix', postoperative skin suture treatment material 'Liquiband', adhesion prevention agent 'Hibicell', and 'Gadix-SP Plus', which enhances the performance of the existing Gadix. [Photo by Hanmi Science]
[Asia Economy Reporter Lee Gwan-joo] Hanmi Science, the holding company of Hanmi Pharmaceutical Group, recently completed the merger with Hanmi Healthcare and appointed former CEO Lim Jong-hoon as president of Hanmi Science to strengthen its healthcare business.
With this, all three children of Hanmi Science CEO Song Young-sook?eldest son Lim Jong-yoon, eldest daughter Joo-hyun, and second son Jong-hoon?have been appointed as co-presidents of Hanmi Science.
Hanmi Healthcare announced on the 14th that it plans to grow its medical device business, which currently records sales in the 30 billion KRW range, to over 50 billion KRW.
The medical device business, which accounts for 30% of Hanmi Healthcare's total sales, has shown a growth rate of about 31% over the past three years, with representative products such as the adhesion barrier "Gadix," which prevents organs or nerves from sticking together during surgery, the surgical hemostatic agent "SurgiGuard," and "LiquiBand," used for post-surgical suturing, all growing steadily.
In particular, Gadix holds a market share of over 40% in the domestic reimbursed adhesion barrier market, recording annual sales in the 20 billion KRW range. Recently, the company strengthened its product lineup by launching "HiVicsell," an adhesion barrier for spinal surgery, the company explained.
Over the past four years, Hanmi Healthcare has formed partnerships with more than ten domestic and international companies, introducing and distributing various products such as inflammation marker test reagents, surgical adhesives, and hemostatic agents. It has also entered the veterinary medical device field, launching products such as animal diagnostic reagents and hemostatic gauze for animals, building a medical device product lineup currently consisting of 33 items. Hanmi Science plans to continue its expansion based on partnerships and to continuously discover competitive products that can enhance synergy with group companies.
A Hanmi Science official said, "The medical device sector is an important pillar of future growth engines that will serve as a core cash cow for the company," adding, "We plan to expand the business to cover the entire medical device field, surpassing the achievements in the surgical therapeutic materials sector that Hanmi Healthcare has focused on."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
